A Single-dose, Open-label, Randomized, Crossover Pivotal Bioequivalence Study in Healthy Participants to Assess the Bioequivalence of Darunavir 675 mg in the Presence of 150 mg Cobicistat When Administered as a Fixed Dose Combination (Darunavir/Cobicistat) Compared to the Co-administration of the Separate Agents (Darunavir and Cobicistat) Under Fed Conditions
Latest Information Update: 21 Jul 2022
At a glance
- Drugs Cobicistat/darunavir (Primary) ; Cobicistat; Darunavir
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development; Janssen-Cilag
- 13 Apr 2021 Status changed from recruiting to completed.
- 09 Apr 2021 This trial is completed (Global End Date: 01 Mar 2021), according to European Clinical Trials Database record.
- 28 Jan 2021 New trial record